Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.

Date publication

juillet 2023

Journal

JAMA network open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal , Pr ENTZ-WERLE Natacha

Tous les auteurs :
Berlanga P, Ndounga-Diakou LA, Aerts I, Corradini N, Ducassou S, Strullu M, de Carli E, André N, Entz-Werle N, Raimbault S, Roumy M, Renouard M, Gueguen G, Plantaz D, Reguerre Y, Cleirec M, Petit A, Puiseux C, Andry L, Klein S, Bodet D, Kanold J, Briandet C, Halfon-Domenech C, Nelken B, Piguet C, Saumet L, Chastagner P, Benadiba J, Millot F, Pluchart C, Schneider P, Thouvenin S, Gambart M, Serre J, Abbou S, Leruste A, Cayzac H, Gandemer V, Laghouati S, Vassal G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37399010

Résumé

Innovative anticancer therapies for children, adolescents, and young adults are regularly prescribed outside their marketing authorization or through compassionate use programs. However, no clinical data of these prescriptions is systematically collected.

Mots clés

Child, Humans, Male, Adolescent, Young Adult, Infant, Child, Preschool, Adult, Female, Off-Label Use, Prospective Studies, Cohort Studies, Antineoplastic Agents, adverse effects, Brain Neoplasms, drug therapy

Référence

JAMA Netw Open. 2023 07 3;6(7):e2321568